167 related articles for article (PubMed ID: 9052418)
21. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
Saarto T; Vehmanen L; Blomqvist C; Elomaa I
J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
[TBL] [Abstract][Full Text] [Related]
22. Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients.
Saarto T; Blomqvist C; Risteli J; Risteli L; Sarna S; Elomaa I
Br J Cancer; 1998 Jul; 78(2):240-5. PubMed ID: 9683300
[TBL] [Abstract][Full Text] [Related]
23. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
Ellmén J; Hakulinen P; Partanen A; Hayes DF
Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
[TBL] [Abstract][Full Text] [Related]
24. Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition.
Haderslev KV; Tjellesen L; Sorensen HA; Staun M
Am J Clin Nutr; 2002 Aug; 76(2):482-8. PubMed ID: 12145026
[TBL] [Abstract][Full Text] [Related]
25. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer.
McCloskey E; Paterson A; Kanis J; Tähtelä R; Powles T
Eur J Cancer; 2010 Feb; 46(3):558-65. PubMed ID: 20031392
[TBL] [Abstract][Full Text] [Related]
26. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
Mäenpää JU; Ala-Fossi SL
Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556
[TBL] [Abstract][Full Text] [Related]
27. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer.
Joensuu H; Holli K; Oksanen H; Valavaara R
Breast Cancer Res Treat; 2000 Oct; 63(3):225-34. PubMed ID: 11110056
[TBL] [Abstract][Full Text] [Related]
28. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
[TBL] [Abstract][Full Text] [Related]
29. Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis.
Lee SJ; Cha CD; Hong H; Choi YY; Chung MS
Breast Cancer; 2024 Jul; 31(4):717-725. PubMed ID: 38671211
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant trials of toremifene vs tamoxifen: the European experience.
Holli K
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):23-7. PubMed ID: 9556787
[TBL] [Abstract][Full Text] [Related]
31. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass.
Filipponi P; Cristallini S; Policani G; Schifini MF; Casciari C; Garinei P
Bone; 2000 Mar; 26(3):269-74. PubMed ID: 10710000
[TBL] [Abstract][Full Text] [Related]
32. Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan.
Yoneda K; Tanji Y; Ikeda N; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
Cancer Lett; 2002 Dec; 186(2):223-30. PubMed ID: 12213292
[TBL] [Abstract][Full Text] [Related]
33. Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women.
Erkkola R; Mattila L; Powles T; Heikkinen J; Toivola B; Korhonen P; Mustonen M
Breast Cancer Res Treat; 2005 Oct; 93(3):277-87. PubMed ID: 16172794
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.
Saarto T; Blomqvist C; Virkkunen P; Elomaa I
J Clin Oncol; 2001 Jan; 19(1):10-7. PubMed ID: 11134190
[TBL] [Abstract][Full Text] [Related]
35. Evolving role of toremifene in the adjuvant setting.
Holli K
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):48-51. PubMed ID: 9165507
[TBL] [Abstract][Full Text] [Related]
36. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Fan M; Kim D
Breast Cancer Res Treat; 2009 Nov; 118(1):81-7. PubMed ID: 19308727
[TBL] [Abstract][Full Text] [Related]
37. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
38. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
[TBL] [Abstract][Full Text] [Related]
39. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N
Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462
[TBL] [Abstract][Full Text] [Related]
40. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
